#POLB Poolbeg Pharma PLC – POLB 001 data to be presented at ASH November 6, 2024 – Posted in: Poolbeg Pharma (POLB)

6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California. Poolbeg’s poster presentation will provide insights into the results…

#POLB Poolbeg Pharma PLC – Interim results for the six months to 30 June 2023 September 13, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update · Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) · Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to…

#POLB Poolbeg Pharma PLC – POLB 001 data to be presented at ASH November 6, 2024 – Posted in: Poolbeg Pharma (POLB)

#POLB Poolbeg Pharma PLC – Interim results for the six months to 30 June 2023 September 13, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL